media centre
IL-15 signaling in NK cell cancer immunotherapy
24 February
Abstract

While cancer has been traditionally treated by chemotherapy, radiation, targeted therapies and surgery, a fifth pillar of cancer treatment, immunotherapy, has emerged over the past 10 years and revolutionized our war on cancer. The benchmark for drugs in this category has been set by the development of CD8 T cell checkpoint (CTLA-4 and PD-1/PD-L1) inhibitors. These therapies effectively expand and reactivate the pool of tumor-specific T cells leading to objective response rates of up to 50% in patients with certain cancers. However, the significant number of patients and cancer types that altogether fail or acquire resistance to these therapies highlights the need for novel immunotherapies that target alternate pathways and effector cells. Thus, there is renewed interest in harnessing the tumor-killing abilities of Natural Killer (NK) cells, though it has proven difficult to efficiently and specifically target these cells cancer patients. The commercial success of T cell checkpoint inhibitors has seen a swam of new biotech companies emerge with innovative or revised strategies that aim to harness the innate non-antigen dependent tumor lysis potential of NK cells. This review will focus on IL-15 biology in NK cells and proposes the development novel therapies aimed at this pathway in humans.

PubMed Link

DOI: 10.1016/j.coi.2016.10.004

media centre
All media
All media
Twitter
Feed
news
news
publications
publications
Looking for a job in a fast-paced and dy...
RT @NatureRevCancer: Our 3rd most downlo...
RT @JoeCursons: The Comp Biol & Bioi...
RT @rhyscienceallan: Here’s a lovely p...
RT @Dr_Nick_Bikes: New pre-print led by ...
RT @Dr_Nick_Bikes: Well deserved recogni...
Great to see @sanofi interested in the N...
RT @Dr_Nick_Bikes: New low budget PR vid...
We're hiring! Fantastic opportunity to w...
We're looking for a highly skilled Senio...
Momentum is building in the allogenic CA...
Are you looking for a new role in a fast...
https://t.co/hbw5kCp9Sa The @HansonWade...
Our CEO & Co-founder, Dr Jai Rautela...
FOUR exciting jobs remain open until Tue...
Could you be the in vivo biologist we’...
RT @cmdenardo: We're hiring! FIVE fantas...
Thanks team! We have an additional 4 res...
4 more exciting positions open! Senior ...
RT @Catherine_DrOz: And this job is with...
Want to join the most exciting immunothe...
Huge congrats to our research collaborat...
Big step forward (2 years ago) for the N...
@HeadNeckMD @DanaFarber @romeerizwan @Dr...
The cancer–natural killer cell immunity cycle
Here at @oNKo_innate, we envisage unique...
RT @oNKo_innate: The Cancer - Natural Ki...
The Cancer - Natural Killer Cell Immunit...
RT @MonashPCCC: @MonashBDI has launched ...
Monash University and oNKo-innate Announce Research Partnership
Are you an experienced oncology biologis...
@oNKo_innate announces research partners...
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies
Immunotherapy biotech scores Gilead partnership
Interest builds in next-generation cancer immunotherapies
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
Announcing research collaboration with Gilead and Kite
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions
Congratulations to our CSO for winning the 2019 Jacques Miller Medal
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Molecular insight into targeting the NK cell immune response to cancer
The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
IL-15 signaling in NK cell cancer immunotherapy
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
Targeting natural killer cells in cancer immunotherapy
CIS is a potent checkpoint in NK cell-mediated tumor immunity
A crucial role for the homeodomain transcription factor Hhex in lymphopoiesis
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo